Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 5/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 3/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.43 |
| ▸ | AGER | Q15109 | 3/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9998343 | 0.89 | CCR5 (0.55) | CCR5CYP3A4CYP2C9CYP2C19SIGMAR1 | |
| SCHEMBL15987361 | 0.86 | CYP2C19 (0.49) | CYP3A4CYP2C9CYP2C19CHRM2CHRM3 | |
| SCHEMBL12033460 | 0.86 | CCR5 (0.51) | CCR5 | |
| SCHEMBL4807302 | 0.85 | PTGDR2 (0.46) | CCR5HTR2APTGDR2AGERCHRM2 | |
| SCHEMBL4807309 | 0.85 | PTGDR2 (0.46) | CCR5HTR2APTGDR2AGERCHRM2 | |
| SCHEMBL28019674 | 0.85 | CCR5 (0.47) | CCR5AGERCHRM2CHRM3MTNR1A | |
| SCHEMBL5689582 | 0.85 | CHRM5 (0.44) | CCR5CYP3A4CYP2C9CYP2C19CHRM2 | |
| SCHEMBL566741 | 0.84 | AGER (0.49) | AGERCHRM2CHRM3MTNR1AOPRM1 | |
| SCHEMBL6202628 | 0.84 | HTR2A (0.51) | HTR2ACHRM3 | |
| SCHEMBL2632144 | 0.82 | SIGMAR1 (0.54) | CCR5CYP3A4CYP2C9CYP2C19HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| WO-2012038081-A1 | SUBSTITUTED BENZAMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2012-03-29 | — | — | WO | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | CCR5 460/4885CYP3A4 2055/4885CYP2C9 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.